开云app官网登录入口网页版-官方正版

#2抑制剂#

221篇内容 | 3210人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995674, encodeId=665819956e4b7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, objectType=article, longId=736572, objectId=7caae365721d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caae365721d, replyNumber=0, likeNumber=103, createdTime=2022-11-07, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caae365721d, moduleTitle=SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7caae365721d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995676, encodeId=1fc019956e668, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, objectType=article, longId=737027, objectId=7b6ee370276e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b6ee370276e, replyNumber=0, likeNumber=119, createdTime=2023-02-28, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6ee370276e, moduleTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b6ee370276e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995671, encodeId=7f7919956e161, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用, objectType=article, longId=732187, objectId=ea2ae32187b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea2ae32187b5, replyNumber=0, likeNumber=72, createdTime=2022-12-16, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea2ae32187b5, moduleTitle=J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea2ae32187b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995663, encodeId=01ec199566361, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, objectType=article, longId=725589, objectId=2d1de25589ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d1de25589ae, replyNumber=0, likeNumber=81, createdTime=2022-12-05, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d1de25589ae, moduleTitle=Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d1de25589ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995656, encodeId=17a419956560a, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, objectType=article, longId=301028, objectId=7a613010288a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a613010288a, replyNumber=0, likeNumber=85, createdTime=2022-12-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a613010288a, moduleTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7a613010288a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995660, encodeId=c57e1995660c6, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, objectType=article, longId=723949, objectId=4428e2394910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4428e2394910, replyNumber=0, likeNumber=111, createdTime=2023-03-04, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4428e2394910, moduleTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4428e2394910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995672, encodeId=c13119956e29d, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, objectType=article, longId=736106, objectId=5cc6e3610606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc6e3610606, replyNumber=0, likeNumber=86, createdTime=2022-11-10, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc6e3610606, moduleTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5cc6e3610606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995673, encodeId=379119956e363, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, objectType=article, longId=736137, objectId=47e3e3613704, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e3e3613704, replyNumber=0, likeNumber=92, createdTime=2023-02-25, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e3e3613704, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47e3e3613704)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995664, encodeId=20bc199566492, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, objectType=article, longId=727301, objectId=6669e2730156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6669e2730156, replyNumber=0, likeNumber=140, createdTime=2023-03-27, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6669e2730156, moduleTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6669e2730156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995658, encodeId=890e1995658a0, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！, objectType=article, longId=301816, objectId=ce7530181602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce7530181602, replyNumber=0, likeNumber=95, createdTime=2022-08-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce7530181602, moduleTitle=Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ce7530181602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995677, encodeId=d3fe19956e75a, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=99, createdTime=2023-08-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995675, encodeId=f62c19956e594, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, objectType=article, longId=737405, objectId=2c50e37405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c50e37405f8, replyNumber=0, likeNumber=99, createdTime=2022-11-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c50e37405f8, moduleTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2c50e37405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995659, encodeId=84bf19956596c, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, objectType=article, longId=723398, objectId=d22be233981c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22be233981c, replyNumber=0, likeNumber=122, createdTime=2022-08-05, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22be233981c, moduleTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d22be233981c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995669, encodeId=9747199566979, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, objectType=article, longId=730645, objectId=8303e3064580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8303e3064580, replyNumber=0, likeNumber=0, createdTime=2022-09-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8303e3064580, moduleTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8303e3064580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995665, encodeId=ca87199566563, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响, objectType=article, longId=727305, objectId=fc4be2730555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc4be2730555, replyNumber=0, likeNumber=100, createdTime=2022-08-05, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc4be2730555, moduleTitle=Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc4be2730555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995668, encodeId=4df2199566800, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估, objectType=article, longId=729619, objectId=4952e2961904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4952e2961904, replyNumber=0, likeNumber=111, createdTime=2022-11-03, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4952e2961904, moduleTitle=Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4952e2961904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995653, encodeId=213c1995653ac, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA Netw Open：钠-葡萄糖共转运蛋白2抑制剂与2型糖尿病患者心血管转归和其他心血管疾病危险因素的相关性, objectType=article, longId=293599, objectId=6fd12935999c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fd12935999c, replyNumber=0, likeNumber=107, createdTime=2022-10-20, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fd12935999c, moduleTitle=JAMA Netw Open：钠-葡萄糖共转运蛋白2抑制剂与2型糖尿病患者心血管转归和其他心血管疾病危险因素的相关性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6fd12935999c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995654, encodeId=5ecb199565440, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, objectType=article, longId=294328, objectId=43cc29432875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cc29432875, replyNumber=0, likeNumber=88, createdTime=2022-03-15, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cc29432875, moduleTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=43cc29432875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995670, encodeId=34b819956e079, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=全球首创EZH2抑制剂他泽司他完成中国首例患者用药, objectType=article, longId=730964, objectId=d910e309647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d910e309647f, replyNumber=0, likeNumber=107, createdTime=2022-07-12, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d910e309647f, moduleTitle=全球首创EZH2抑制剂他泽司他完成中国首例患者用药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d910e309647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995666, encodeId=9f441995666bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较, objectType=article, longId=728165, objectId=9339e28165c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9339e28165c0, replyNumber=0, likeNumber=110, createdTime=2022-08-29, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9339e28165c0, moduleTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9339e28165c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

SGLT2抑制剂、DPP-4抑制剂和磺酰脲类药物在糖尿病酮症酸中毒方面的安全性比较

2022-11-07

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险

2023-02-28

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

J Allergy Clin Immunol：脱氧核糖核酸2抑制剂对银屑病的分子和临床作用

2022-12-16

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：糖尿病肾病患者中SGLT2抑制剂与心血管、肾脏和安全性结局的关系

2022-12-05

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！

2022-12-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险

2023-03-04

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素

2022-11-10

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：SGLT2抑制剂在糖尿病合并心力衰竭患者中的当代应用情况

2023-02-25

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤

2023-03-27

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：SGLT2抑制剂可降低糖尿病肾病患者的多种不良临床结局风险！

2022-08-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2023-08-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭

2022-11-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰

2022-08-05

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性

2022-09-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Cardiovasc Diabetol：不同SGLT2抑制剂对糖尿病患者心血管不良结局风险的影响

2022-08-05

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估

2022-11-03

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA Netw Open：钠-葡萄糖共转运蛋白2抑制剂与2型糖尿病患者心血管转归和其他心血管疾病危险因素的相关性

2022-10-20

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益

2022-03-15

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

全球首创EZH2抑制剂他泽司他完成中国首例患者用药

2022-07-12

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与二甲双胍治疗2型糖尿病患者的心血管结局比较

2022-08-29

科室
- - 订阅+
  - 更多科室
工具
服务